Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases
GSK
The ambition of the partnership is to treat immune-related diseases more precisely with existing therapies and to rapidly develop new ones. The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) combines University and GSK expertise in the science of the immune system, AI and clinical development with access to patients and their data provided by Cambridge University Hospitals. GSK is investing more than £50 million in CG-TIC, further strengthening Cambridge’s position as Europe’s
din zilele anterioare